Chetna Dureja
YOU?
Author Swipe
View article: Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Specific Ribotypes
Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Specific Ribotypes Open
Background Reduced vancomycin (VAN) susceptibility in clinical Clostridioides difficile isolates is correlated with poor clinical outcomes. However, factors associated with infection with these strains are unknown. The goal of this study w…
View article: Identification of critical amino acids in the DNA binding domain of LuxO: Lessons from a constitutive active LuxO
Identification of critical amino acids in the DNA binding domain of LuxO: Lessons from a constitutive active LuxO Open
Quorum sensing plays a vital role in the environmental and host life cycles of Vibrio cholerae . The quorum-sensing circuit involves the consorted action of autoinducers, small RNAs, and regulatory proteins to control a plethora of physiol…
View article: Evaluation of <i>Fusobacterium nucleatum</i> Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target
Evaluation of <i>Fusobacterium nucleatum</i> Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target Open
Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial age…
View article: Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response
Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response Open
Background Epidemiologic studies have shown decreasing vancomycin susceptibility among clinical Clostridioides difficile isolates, but the impact on patient outcomes is unknown. We hypothesized that reduced vancomycin susceptibility would …
View article: <i>In vivo</i> evaluation of <i>Clostridioides difficile</i> enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
<i>In vivo</i> evaluation of <i>Clostridioides difficile</i> enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy Open
Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficil…
View article: <i>In vivo</i>evaluation of<i>Clostridioides difficile</i>enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
<i>In vivo</i>evaluation of<i>Clostridioides difficile</i>enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy Open
Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile…
View article: Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile Open
Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decr…
View article: Synthesis and evaluation of phenylimidazole FabK inhibitors as new Anti-C. Difficile agents
Synthesis and evaluation of phenylimidazole FabK inhibitors as new Anti-C. Difficile agents Open
View article: Surveillance of <i>Clostridioides difficile</i> Antimicrobial Resistance in the United States
Surveillance of <i>Clostridioides difficile</i> Antimicrobial Resistance in the United States Open
Journal Article Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States Get access Anne J Gonzales-Luna, Anne J Gonzales-Luna Department of Pharmacy Practice and Translational Research, University of Houston …
View article: 380. A molecular epidemiological exploration of reduced vancomycin susceptibility in <i>Clostridioides difficile</i>
380. A molecular epidemiological exploration of reduced vancomycin susceptibility in <i>Clostridioides difficile</i> Open
Background Use of vancomycin to treat Clostridioides difficile infection (CDI) has increased following recent IDSA/SHEA treatment guideline updates, applying a selection pressure for resistance development. We previously demonstrated acqui…
View article: 401. Rigor and Reproducibility of <i>Clostridioides difficile</i> susceptibility testing
401. Rigor and Reproducibility of <i>Clostridioides difficile</i> susceptibility testing Open
Background The growth and susceptibility testing of anaerobic bacteria presents many unique challenges. The Clinical Laboratory Standards Institute (CLSI) recommends performing minimum inhibitory concentration (MIC) testing for C. difficil…
View article: Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant <i>Clostridioides difficile</i>
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant <i>Clostridioides difficile</i> Open
Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decr…
View article: Mechanisms and impact of antimicrobial resistance in Clostridioides difficile
Mechanisms and impact of antimicrobial resistance in Clostridioides difficile Open
View article: Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy Open
Protein kinase C (PKC) isozymes play major roles in human diseases, including cancer. Yet, the poor understanding of isozymes-specific functions and the limited availability of selective pharmacological modulators of PKC isozymes have limi…